Our major accomplishments this year are: (1) sequencing the VHL gene including promoter, exons, introns, and flanks altogether comprising 16kb; (2) identification of pVHL target genes by using differential display technology; to date 120 primer pairs were tested and so far two down regulated genes identified, namely, HL31 a ribosomal protein gene overexpressed in colon cancer and FAP, and an intracellular receptor for PKC (a homolog of the beta subunit of G proteins). (3) analysis of the methylation of the VHL promoter in renal carcinoma: 40 cell lines were established of Meth+ RCA cells transfected stably with VHL minigenes driven by the VHL promoter. The minigenes appeared actively transcribed and the transfected promoter was not methylated suggesting that the mechanism protecting the endogenous promoter is damaged. (4) The 3p21.3 TSG: the 700kb cosmid-P1 contig is now completely sequenced jointly by The Sanger Centre (Hinxton, UK) and The WU Genome Sequencing Center (St. Louis, USA). We are using traditional laboratory and computational methods (gene identification software) to identify the cancer genes. At the present time (Spt. 23rd) 20 new genes were isolated and investigated to identify their function and status in cancer specimen. Several important genes with potential applications in medicine were identified among these genes, they include: two new semaphorin genes (provide guidance cues in axon growth in CNS); two new genes with hyaluronidase activity, involved in angiogenesis and probably metastasis; 3 genes with SH domains; genes with RNA binding motifs; a novel MAPKAP kinase; and an unknown gene with motifs involved in cell death. About 80 Grail exons were identified and analysed for mutations or rearrangements in lung cancer. At the present time SSCP did not detect frequent mutations neither in the genes or Grail exons. The 3p12 TSG: the original large, 8mb, deletion is now narrowed by ROH and overlapping homozygous deletions, of which one is actually an intrageneic deletion that inactivates a novel gene, by sequence analysis has homology to a known TSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC008579-03
Application #
2463742
Study Section
Special Emphasis Panel (LIB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Ivanov, Sergey V; Ivanova, Alla V; Salnikow, Konstantin et al. (2008) Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 370:536-40
Angeloni, D; Danilkovitch-Miagkova, A; Ivanova, T et al. (2007) Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 26:4499-512
Ivanova, A V; Ivanov, S V; Pascal, V et al. (2007) Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J Pathol 211:591-601
Yi Lo, Paulisally Hau; Chung Leung, Alfred Chi; Xiong, Wenjun et al. (2006) Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett 234:184-92
Miller, A D; Vigdorovich, V; Strong, R K et al. (2006) Hyal2, where are you? Osteoarthritis Cartilage 14:1315-7
Angeloni, Debora; ter Elst, Arja; Wei, Ming Hui et al. (2006) Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes. Genes Chromosomes Cancer 45:676-91
Yau, Wing Lung; Lung, Hong Lok; Zabarovsky, Eugene R et al. (2006) Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer 119:2821-6
Kuzmin, Igor; Geil, Laura; Gibson, Lauren et al. (2005) Transcriptional regulator CTCF controls human interleukin 1 receptor-associated kinase 2 promoter. J Mol Biol 346:411-22
Li, Jingfeng; Wang, Fuli; Haraldson, Klas et al. (2004) Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res 64:6438-43
Ivanov, Sergey V; Ward, Jerrold M; Tessarollo, Lino et al. (2004) Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol 165:1007-18

Showing the most recent 10 out of 38 publications